Tag
5 articles
Novo Holdings, the investment firm behind Novo Nordisk, is backing a new fund to support Italian drug startups, extending its investment reach beyond Denmark.
LifeSciBench is a comprehensive benchmark developed by OpenAI that evaluates AI models on real-life science research tasks, focusing on reasoning and decision-making rather than simple recall. It uses expert-authored rubrics to assess how well AI systems can handle complex scientific workflows.
OpenAI introduces enhanced GPT-Rosalind with advanced biological reasoning, medicinal chemistry expertise, and genomics analysis capabilities for life sciences research.
This article explains GPT-Rosalind, OpenAI's new domain-specific AI model for drug discovery and life sciences research, and how it represents a shift toward AI systems that enhance scientific reasoning rather than just automate tasks.
OpenAI introduces GPT-Rosalind, a specialized AI model designed to accelerate drug discovery, genomics analysis, and protein reasoning in life sciences research.
